ImmunoMet is a clinical stage biotech targeting cellular metabolism to develop novel anti-tumor and anti-fibrotic therapies. Our lead molecule, IM156, is an protein complex 1 (PC1) inhibitor with demonstrated impressive in-vivo efficacy in resistant solid tumors. IM156 is the first potent PC1 inhibitor to complete Phase 1 with a good safety profile. ImmunoMet has a second program in fibrosis and plans to enter the clinic with IM156 in 2H2020. The company was founded in 2015, is headquartered in the Houston JLABs near MD Anderson, and has raised $19M to date.
Company HQ State:
Company HQ Country:
Main Therapeutic Focus:
Lead Product in Development:
Development Phase of Primary Product:
Number Of Unlicensed Products (For Which You Are Seeking Partners):